Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 19054631)


Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV.

Barnett PG, Sorensen JL, Wong W, Haug NA, Hall SM.

Drug Alcohol Depend. 2009 Feb 1;100(1-2):115-21. doi: 10.1016/j.drugalcdep.2008.09.017. Epub 2008 Dec 3.


Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.

Alistar SS, Owens DK, Brandeau ML.

PLoS Med. 2011 Mar;8(3):e1000423. doi: 10.1371/journal.pmed.1000423. Epub 2011 Mar 1.


The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care.

Gardner EM, Maravi ME, Rietmeijer C, Davidson AJ, Burman WJ.

Appl Health Econ Health Policy. 2008;6(2-3):145-55. doi: 10.2165/00148365-200806020-00006.


Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial.

Berg KM, Litwin A, Li X, Heo M, Arnsten JH.

Drug Alcohol Depend. 2011 Jan 15;113(2-3):192-9. doi: 10.1016/j.drugalcdep.2010.07.025. Epub 2010 Sep 15.


Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial.

Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, Tulsky JP, Barnett P, Hall S.

Drug Alcohol Depend. 2007 Apr 17;88(1):54-63. Epub 2006 Oct 23.


Voucher incentives improve linkage to and retention in care among HIV-infected drug users in Chennai, India.

Solomon SS, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS, Balakrishnan P, Mehta SH, Solomon S, Lucas GM.

Clin Infect Dis. 2014 Aug 15;59(4):589-95. doi: 10.1093/cid/ciu324. Epub 2014 May 6.


Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.

Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP.

J Manag Care Pharm. 2009 Jan-Feb;15(1):32-41.


Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment.

Gonzalez A, Mimiaga MJ, Israel J, Andres Bedoya C, Safren SA.

AIDS Behav. 2013 Jan;17(1):168-73. doi: 10.1007/s10461-012-0319-6.


Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics.

Berg KM, Mouriz J, Li X, Duggan E, Goldberg U, Arnsten JH.

Contemp Clin Trials. 2009 Sep;30(5):481-9. doi: 10.1016/j.cct.2009.05.003. Epub 2009 Jun 6.


Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost.

Avants SK, Margolin A, Sindelar JL, Rounsaville BJ, Schottenfeld R, Stine S, Cooney NL, Rosenheck RA, Li SH, Kosten TR.

Am J Psychiatry. 1999 Jan;156(1):27-33.


Simplification of antiretroviral therapy: a good choice for our patients and the sustainability of our health care system.

González Rivas L, Sánchez Gómez E, Sánchez del Moral R, Grutzmancher Saiz S, Pujol de la Llave E, Bocanegra Martín C.

Farm Hosp. 2011 Nov-Dec;35(6):317-21. doi: 10.1016/j.farma.2011.01.003. Epub 2011 Oct 21. English, Spanish.


Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial.

Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, Imrie J, Bärnighausen T, Rekacewicz C, Bazin B, Newell ML, Dabis F; ANRS 12249 TasP Study Group.

Trials. 2013 Jul 23;14:230. doi: 10.1186/1745-6215-14-230.


[The pharmacoeconomics of antiretroviral drugs and the role of adherence].

Bargiacchi O, Brondolo R, Rizzo G, Garavelli PL.

Infez Med. 2012 Dec;20(4):245-50. Review. Italian.


"Damaging what wasn't damaged already": psychological tension and antiretroviral adherence among HIV-infected methadone-maintained drug users.

Batchelder AW, Brisbane M, Litwin AH, Nahvi S, Berg KM, Arnsten JH.

AIDS Care. 2013;25(11):1370-4. doi: 10.1080/09540121.2013.766303. Epub 2013 Feb 13.


Psychiatric and social barriers to HIV medication adherence in a triply diagnosed methadone population.

Palmer NB, Salcedo J, Miller AL, Winiarski M, Arno P.

AIDS Patient Care STDS. 2003 Dec;17(12):635-44.


Linking opioid-dependent hospital patients to drug treatment: Health care use and costs 6 months after randomization.

Barnett PG, Masson CL, Sorensen JL, Wong W, Hall S.

Addiction. 2006 Dec;101(12):1797-804.


Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention.

Berg KM, Litwin AH, Li X, Heo M, Arnsten JH.

Clin Infect Dis. 2011 Nov;53(9):936-43. doi: 10.1093/cid/cir537. Epub 2011 Sep 2.


Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.

Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, Meikleham E, Schechter MT, Anis AH.

CMAJ. 2012 Apr 3;184(6):E317-28. doi: 10.1503/cmaj.110669. Epub 2012 Mar 12.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk